Log In
Print
BCIQ
Print
Print this Print this
 

doxepin (Silenor)

Also known as: SO-101

  Manage Alerts
Collapse Summary General Information
Company Pernix Therapeutics Holdings Inc.
DescriptionLow-dose tricyclic doxepin
Molecular Target Histamine H1 receptor (HRH1) ; Histamine receptor
Mechanism of ActionHistamine H1 receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInsomnia
Indication DetailsTreat insomnia; Treat insomnia characterized by nocturnal awakenings and/or early morning awakenings; Treat insomnia in elderly patients; Treat primary chronic insomnia; Treat primary sleep maintenance insomnia; Treat transient insomnia
Regulatory Designation

Partner

CJ Group; Endo International plc; Procter & Gamble Co.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today